Skip to main content
Erschienen in: Current Treatment Options in Cardiovascular Medicine 7/2016

01.07.2016 | Vascular Disease (I Weinberg, Section Editor)

Medical Therapy in Peripheral Artery Disease and Critical Limb Ischemia

verfasst von: T. Raymond Foley, MD, Stephen W. Waldo, MD, Ehrin J. Armstrong, MD, MSc

Erschienen in: Current Treatment Options in Cardiovascular Medicine | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Opinion statement

Peripheral artery disease (PAD) comprises atherosclerosis of the aorta and lower extremities. Many patients with PAD are asymptomatic, while others present with intermittent claudication (IC) or critical limb ischemia (CLI). Defined as rest pain or tissue loss that persists for >2 weeks, CLI represents the most severe clinical manifestation of PAD and is associated with an increased risk of limb loss and death. Patients with PAD, including those with CLI, are underdiagnosed and undertreated. In addition to smoking cessation, medical therapy with an antiplatelet agent and statin is recommended for all patients with PAD. Regular exercise has been shown to improve walking distance and quality of life in patients with symptomatic PAD and should be incorporated into each patient’s treatment plan. In patients who have CLI and in those with persistent lifestyle-limiting claudication despite optimal medical therapy and an exercise program, revascularization is indicated for limb salvage and symptom relief, respectively. Consensus guidelines currently support an endovascular first approach to revascularization in the majority of cases. Surgical procedures provide an alternative to endovascular therapy in select cases.
Literatur
1.
2.
Zurück zum Zitat Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996;25(6):1172–81.CrossRefPubMed Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996;25(6):1172–81.CrossRefPubMed
7.
Zurück zum Zitat Minar E. Critical limb ischaemia. Hamostaseologie. 2009;29(1):102–9.PubMed Minar E. Critical limb ischaemia. Hamostaseologie. 2009;29(1):102–9.PubMed
9.
Zurück zum Zitat Pipinos II, Judge AR, Selsby JT, et al. The myopathy of peripheral arterial occlusive disease: part 1. Functional and histomorphological changes and evidence for mitochondrial dysfunction. Vasc Endovasc Surg. 2008;41(6):481–9. doi:10.1177/1538574407311106.CrossRef Pipinos II, Judge AR, Selsby JT, et al. The myopathy of peripheral arterial occlusive disease: part 1. Functional and histomorphological changes and evidence for mitochondrial dysfunction. Vasc Endovasc Surg. 2008;41(6):481–9. doi:10.​1177/​1538574407311106​.CrossRef
10.
Zurück zum Zitat Bertelè V, Roncaglioni MC, Pangrazzi J, Terzian E, Tognoni EG. Clinical outcome and its predictors in 1560 patients with critical leg ischaemia. Chronic critical Leg ischaemia group. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 1999;18(5):401–10. doi:10.1053/ejvs.1999.0934.CrossRef Bertelè V, Roncaglioni MC, Pangrazzi J, Terzian E, Tognoni EG. Clinical outcome and its predictors in 1560 patients with critical leg ischaemia. Chronic critical Leg ischaemia group. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 1999;18(5):401–10. doi:10.​1053/​ejvs.​1999.​0934.CrossRef
13.
Zurück zum Zitat Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the american association for vascular surgery/society for vascular surgery, society for cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the ACC/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): endorsed by the american association of cardiovascular and pulmonary rehabilitation; national heart, lung, and blood institute; society for vascular nursing; TransAtlantic inter-society consensus; and vascular disease foundation. Circulation. 2006;113(11):e463–654. doi:10.1161/CIRCULATIONAHA.106.174526.CrossRefPubMed Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the american association for vascular surgery/society for vascular surgery, society for cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the ACC/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): endorsed by the american association of cardiovascular and pulmonary rehabilitation; national heart, lung, and blood institute; society for vascular nursing; TransAtlantic inter-society consensus; and vascular disease foundation. Circulation. 2006;113(11):e463–654. doi:10.​1161/​CIRCULATIONAHA.​106.​174526.CrossRefPubMed
14.
16.
Zurück zum Zitat Jonason T, Bergström R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987;221(3):253–60.CrossRefPubMed Jonason T, Bergström R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand. 1987;221(3):253–60.CrossRefPubMed
17.
Zurück zum Zitat Quick CR, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg. 1982;69(Suppl):S24–6.CrossRefPubMed Quick CR, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg. 1982;69(Suppl):S24–6.CrossRefPubMed
18.
Zurück zum Zitat Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Semin Vasc Surg. 1999;12(2):123–37.PubMed Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Semin Vasc Surg. 1999;12(2):123–37.PubMed
20.
Zurück zum Zitat Armstrong EJ, Wu J, Singh GD, et al. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. J Vasc Surg. 2014;60(6):1565–71. doi:10.1016/j.jvs.2014.08.064.CrossRefPubMed Armstrong EJ, Wu J, Singh GD, et al. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. J Vasc Surg. 2014;60(6):1565–71. doi:10.​1016/​j.​jvs.​2014.​08.​064.CrossRefPubMed
25.
Zurück zum Zitat Hiatt WR, Regensteiner JG, Wolfel EE, Carry MR, Brass EP. Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease. J Appl Physiol Bethesda Md 1985. 1996;81(2):780–8. Hiatt WR, Regensteiner JG, Wolfel EE, Carry MR, Brass EP. Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease. J Appl Physiol Bethesda Md 1985. 1996;81(2):780–8.
26.
Zurück zum Zitat Collins TC, Lunos S, Carlson T, et al. Effects of a home-based walking intervention on mobility and quality of life in people with diabetes and peripheral arterial disease: a randomized controlled trial. Diabetes Care. 2011;34(10):2174–9. doi:10.2337/dc10-2399.CrossRefPubMedPubMedCentral Collins TC, Lunos S, Carlson T, et al. Effects of a home-based walking intervention on mobility and quality of life in people with diabetes and peripheral arterial disease: a randomized controlled trial. Diabetes Care. 2011;34(10):2174–9. doi:10.​2337/​dc10-2399.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Bendermacher BLW, Willigendael EM, Teijink JAW, Prins MH. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev. 2006; (2):CD005263. doi:10.1002/14651858.CD005263.pub2. Bendermacher BLW, Willigendael EM, Teijink JAW, Prins MH. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev. 2006; (2):CD005263. doi:10.​1002/​14651858.​CD005263.​pub2.
28.
Zurück zum Zitat Nicolaï SPA, Teijink JAW, Prins MH. Exercise therapy in peripheral arterial disease study group. Multicenter randomized clinical trial of supervised exercise therapy with or without feedback versus walking advice for intermittent claudication. J Vasc Surg. 2010;52(2):348–55. doi:10.1016/j.jvs.2010.02.022.CrossRefPubMed Nicolaï SPA, Teijink JAW, Prins MH. Exercise therapy in peripheral arterial disease study group. Multicenter randomized clinical trial of supervised exercise therapy with or without feedback versus walking advice for intermittent claudication. J Vasc Surg. 2010;52(2):348–55. doi:10.​1016/​j.​jvs.​2010.​02.​022.CrossRefPubMed
29.
31.
Zurück zum Zitat Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation. 2012;125(1):130–9. doi:10.1161/CIRCULATIONAHA.111.075770.CrossRefPubMed Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation. 2012;125(1):130–9. doi:10.​1161/​CIRCULATIONAHA.​111.​075770.CrossRefPubMed
32.•
Zurück zum Zitat Armstrong EJ, Chen DC, Westin GG, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014;3(2):e000697. doi:10.1161/JAHA.113.000697. A retrospective study demonstrating an association between adherence to four guideline-recommended therapies (smoking cessation, aspirin, statin medication and ACE-inhibitors) and reduced rates of MACE, MALE and all-cause mortality at 3 years.CrossRefPubMedPubMedCentral Armstrong EJ, Chen DC, Westin GG, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014;3(2):e000697. doi:10.​1161/​JAHA.​113.​000697. A retrospective study demonstrating an association between adherence to four guideline-recommended therapies (smoking cessation, aspirin, statin medication and ACE-inhibitors) and reduced rates of MACE, MALE and all-cause mortality at 3 years.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317–24.CrossRefPubMed Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317–24.CrossRefPubMed
34.••
Zurück zum Zitat Subherwal S, Patel MR, Kober L, et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation. 2012;126(11):1345–54. doi:10.1161/CIRCULATIONAHA.112.108787. An important population based cohort study of Danish patients with PAD and/or CAD that demonstrated underuse of guideline-driven medical therapy that was most pronounced among patients with PAD. Of these patients, approximately 50% were prescribed an antiplatelet medication, 40% used a statin and 20% used an ACE-inhibitor. Patients with PAD were significantly less likely than those with CAD to receive a statin or antiplatelet medication.CrossRefPubMed Subherwal S, Patel MR, Kober L, et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation. 2012;126(11):1345–54. doi:10.​1161/​CIRCULATIONAHA.​112.​108787. An important population based cohort study of Danish patients with PAD and/or CAD that demonstrated underuse of guideline-driven medical therapy that was most pronounced among patients with PAD. Of these patients, approximately 50% were prescribed an antiplatelet medication, 40% used a statin and 20% used an ACE-inhibitor. Patients with PAD were significantly less likely than those with CAD to receive a statin or antiplatelet medication.CrossRefPubMed
35.
36.
Zurück zum Zitat Robless PA, Okonko D, Lintott P, Mansfield AO, Mikhailidis DP, Stansby GP. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2003;25(1):16–22.CrossRef Robless PA, Okonko D, Lintott P, Mansfield AO, Mikhailidis DP, Stansby GP. Increased platelet aggregation and activation in peripheral arterial disease. Eur J Vasc Endovasc Surg Off J Eur Soc Vasc Surg. 2003;25(1):16–22.CrossRef
37.
Zurück zum Zitat Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301(18):1909–19. doi:10.1001/jama.2009.623.CrossRefPubMed Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301(18):1909–19. doi:10.​1001/​jama.​2009.​623.CrossRefPubMed
38.
Zurück zum Zitat Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.CrossRef Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.CrossRef
39.
Zurück zum Zitat Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.CrossRefPubMedPubMedCentral Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Fowkes FGR, Price JF, Stewart MCW, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303(9):841–8. doi:10.1001/jama.2010.221.CrossRefPubMed Fowkes FGR, Price JF, Stewart MCW, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010;303(9):841–8. doi:10.​1001/​jama.​2010.​221.CrossRefPubMed
41.
Zurück zum Zitat CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee. Lancet Lond Engl. 1996;348(9038):1329–39.CrossRef CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE steering committee. Lancet Lond Engl. 1996;348(9038):1329–39.CrossRef
45.
Zurück zum Zitat Armstrong EJ, Anderson DR, Yeo K-K, et al. Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. J Vasc Surg. 2015;62(1):157–165.e1. doi:10.1016/j.jvs.2015.01.051.CrossRefPubMed Armstrong EJ, Anderson DR, Yeo K-K, et al. Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. J Vasc Surg. 2015;62(1):157–165.e1. doi:10.​1016/​j.​jvs.​2015.​01.​051.CrossRefPubMed
46.•
Zurück zum Zitat Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013;127(14):1522–1529, 1529e1-e6. doi:10.1161/CIRCULATIONAHA.112.000679. Important trial demonstrating efficacy of PAR-1 antagonism with vorapaxar in reducing rates of acute limb ischemia and peripheral revascularization in patients with PAD. Bonaca MP, Scirica BM, Creager MA, et al. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50. Circulation. 2013;127(14):1522–1529, 1529e1-e6. doi:10.​1161/​CIRCULATIONAHA.​112.​000679. Important trial demonstrating efficacy of PAR-1 antagonism with vorapaxar in reducing rates of acute limb ischemia and peripheral revascularization in patients with PAD.
48.
Zurück zum Zitat Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000;342(3):145–53. doi:10.1056/NEJM200001203420301.CrossRefPubMed Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000;342(3):145–53. doi:10.​1056/​NEJM200001203420​301.CrossRefPubMed
49.•
Zurück zum Zitat Armstrong EJ, Chen DC, Singh GD, Amsterdam EA, Laird JR. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia. Vasc Med Lond Engl. 2015;20(3):237–44. doi:10.1177/1358863X15574321. An observational cohort study that demonstrating reduced rates of MACE and overall mortality among patients with CLI prescribed an ACE or ARB.CrossRef Armstrong EJ, Chen DC, Singh GD, Amsterdam EA, Laird JR. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia. Vasc Med Lond Engl. 2015;20(3):237–44. doi:10.​1177/​1358863X15574321​. An observational cohort study that demonstrating reduced rates of MACE and overall mortality among patients with CLI prescribed an ACE or ARB.CrossRef
50.
Zurück zum Zitat Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med. 2006;144(9):660–4.CrossRefPubMed Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Ann Intern Med. 2006;144(9):660–4.CrossRefPubMed
51.
Zurück zum Zitat Ahimastos AA, Walker PJ, Askew C, et al. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA. 2013;309(5):453–60. doi:10.1001/jama.2012.216237.CrossRefPubMed Ahimastos AA, Walker PJ, Askew C, et al. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA. 2013;309(5):453–60. doi:10.​1001/​jama.​2012.​216237.CrossRefPubMed
52.
Zurück zum Zitat Notice of Retraction: Ahimastos AA, et al. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA. 2013; 309(5):453–460. JAMA. 2015; 314(14):1520–1521. doi:10.1001/jama.2015.10811. Notice of Retraction: Ahimastos AA, et al. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA. 2013; 309(5):453–460. JAMA. 2015; 314(14):1520–1521. doi:10.​1001/​jama.​2015.​10811.
54.
Zurück zum Zitat Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA. 1997;278(4):313–21.CrossRefPubMed Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA. 1997;278(4):313–21.CrossRefPubMed
55.
Zurück zum Zitat Aronow WS, Ahn C. Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol. 2002;90(7):789–91.CrossRefPubMed Aronow WS, Ahn C. Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol. 2002;90(7):789–91.CrossRefPubMed
57.
Zurück zum Zitat Westin GG, Armstrong EJ, Bang H, et al. Association Between Statin Medications and Mortality, Major Adverse Cardiovascular Event, and Amputation-Free Survival in Patients With Critical Limb Ischemia. J Am Coll Cardiol. 2014;63(7):682–90. doi:10.1016/j.jacc.2013.09.073.CrossRefPubMed Westin GG, Armstrong EJ, Bang H, et al. Association Between Statin Medications and Mortality, Major Adverse Cardiovascular Event, and Amputation-Free Survival in Patients With Critical Limb Ischemia. J Am Coll Cardiol. 2014;63(7):682–90. doi:10.​1016/​j.​jacc.​2013.​09.​073.CrossRefPubMed
60.
Zurück zum Zitat Collaborative Group ADVANCE, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72. doi:10.1056/NEJMoa0802987.CrossRef Collaborative Group ADVANCE, Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72. doi:10.​1056/​NEJMoa0802987.CrossRef
63.
69.
Zurück zum Zitat Aviado DM, Porter JM. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy. 1984;4(6):297–307.CrossRefPubMed Aviado DM, Porter JM. Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy. 1984;4(6):297–307.CrossRefPubMed
70.
Zurück zum Zitat Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ Can Med Assoc J J Assoc Medicale Can. 1996;155(8):1053–9. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ Can Med Assoc J J Assoc Medicale Can. 1996;155(8):1053–9.
74.
Zurück zum Zitat Barradell LB, Brogden RN. Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging. 1996;8(4):299–322.CrossRefPubMed Barradell LB, Brogden RN. Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging. 1996;8(4):299–322.CrossRefPubMed
76.
Zurück zum Zitat Goldsmith DR, Wellington K. Naftidrofuryl: a review of its use in the treatment of intermittent claudication. Drugs Aging. 2005;22(11):967–77.CrossRefPubMed Goldsmith DR, Wellington K. Naftidrofuryl: a review of its use in the treatment of intermittent claudication. Drugs Aging. 2005;22(11):967–77.CrossRefPubMed
77.
Zurück zum Zitat Meng Y, Squires H, Stevens JW, et al. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. Angiology. 2014;65(3):190–7. doi:10.1177/0003319712474335.CrossRefPubMed Meng Y, Squires H, Stevens JW, et al. Cost-effectiveness of cilostazol, naftidrofuryl oxalate, and pentoxifylline for the treatment of intermittent claudication in people with peripheral arterial disease. Angiology. 2014;65(3):190–7. doi:10.​1177/​0003319712474335​.CrossRefPubMed
79.
Zurück zum Zitat Collaborative overview of randomised trials of antiplatelet therapy—II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists’ Collaboration. BMJ. 1994; 308(6922):159–168. Collaborative overview of randomised trials of antiplatelet therapy—II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists’ Collaboration. BMJ. 1994; 308(6922):159–168.
80.
Zurück zum Zitat Belch JJF, Dormandy J, CASPAR Writing Committee, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52(4):825–33. doi:10.1016/j.jvs.2010.04.027. 833.e1-e2.CrossRefPubMed Belch JJF, Dormandy J, CASPAR Writing Committee, et al. Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg. 2010;52(4):825–33. doi:10.​1016/​j.​jvs.​2010.​04.​027. 833.e1-e2.CrossRefPubMed
81.
Zurück zum Zitat Investigators WAVET, Anand S, Yusuf S, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357(3):217–27. doi:10.1056/NEJMoa065959.CrossRef Investigators WAVET, Anand S, Yusuf S, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007;357(3):217–27. doi:10.​1056/​NEJMoa065959.CrossRef
82.
Zurück zum Zitat Bonaca MP, Gutierrez JA, Creager MA, et al. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50. Circulation. 2016:CIRCULATIONAHA.115.019355. doi:10.1161/CIRCULATIONAHA.115.019355. Bonaca MP, Gutierrez JA, Creager MA, et al. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from TRA2°P-TIMI 50. Circulation. 2016:CIRCULATIONAHA.115.019355. doi:10.​1161/​CIRCULATIONAHA.​115.​019355.
83.•
Zurück zum Zitat Cooke JP, Losordo DW. Modulating the vascular response to limb ischemia: angiogenic and cell therapies. Circ Res. 2015;116(9):1561–78. doi:10.1161/CIRCRESAHA.115.303565. This article provides a comprehensive review of the scientific rationale for angiogenic and cell therapies in PAD and CLI, as well as a concise summary of the relevant trials that have been conducted to date.CrossRefPubMedPubMedCentral Cooke JP, Losordo DW. Modulating the vascular response to limb ischemia: angiogenic and cell therapies. Circ Res. 2015;116(9):1561–78. doi:10.​1161/​CIRCRESAHA.​115.​303565. This article provides a comprehensive review of the scientific rationale for angiogenic and cell therapies in PAD and CLI, as well as a concise summary of the relevant trials that have been conducted to date.CrossRefPubMedPubMedCentral
85.
86.
Zurück zum Zitat Makino H, Aoki M, Hashiya N, et al. Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Arterioscler Thromb Vasc Biol. 2012;32(10):2503–9. doi:10.1161/ATVBAHA.111.244632.CrossRefPubMed Makino H, Aoki M, Hashiya N, et al. Long-term follow-up evaluation of results from clinical trial using hepatocyte growth factor gene to treat severe peripheral arterial disease. Arterioscler Thromb Vasc Biol. 2012;32(10):2503–9. doi:10.​1161/​ATVBAHA.​111.​244632.CrossRefPubMed
87.
Zurück zum Zitat Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet Lond Engl. 2002;360(9331):427–35. doi:10.1016/S0140-6736(02)09670-8.CrossRef Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet Lond Engl. 2002;360(9331):427–35. doi:10.​1016/​S0140-6736(02)09670-8.CrossRef
90.
Zurück zum Zitat Duong Van Huyen J-P, Smadja DM, Bruneval P, et al. Bone marrow-derived mononuclear cell therapy induces distal angiogenesis after local injection in critical leg ischemia. Mod Pathol Off J U S Can Acad Pathol Inc. 2008;21(7):837–46. doi:10.1038/modpathol.2008.48. Duong Van Huyen J-P, Smadja DM, Bruneval P, et al. Bone marrow-derived mononuclear cell therapy induces distal angiogenesis after local injection in critical leg ischemia. Mod Pathol Off J U S Can Acad Pathol Inc. 2008;21(7):837–46. doi:10.​1038/​modpathol.​2008.​48.
91.
92.
Zurück zum Zitat Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care. 2005;28(9):2155–60.CrossRefPubMed Huang P, Li S, Han M, Xiao Z, Yang R, Han ZC. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care. 2005;28(9):2155–60.CrossRefPubMed
Metadaten
Titel
Medical Therapy in Peripheral Artery Disease and Critical Limb Ischemia
verfasst von
T. Raymond Foley, MD
Stephen W. Waldo, MD
Ehrin J. Armstrong, MD, MSc
Publikationsdatum
01.07.2016
Verlag
Springer US
Erschienen in
Current Treatment Options in Cardiovascular Medicine / Ausgabe 7/2016
Print ISSN: 1092-8464
Elektronische ISSN: 1534-3189
DOI
https://doi.org/10.1007/s11936-016-0464-8

Weitere Artikel der Ausgabe 7/2016

Current Treatment Options in Cardiovascular Medicine 7/2016 Zur Ausgabe

Vascular Disease (I Weinberg, Section Editor)

Interventions for Varicose Veins: Beyond Ablation

Cardio-oncology (M Fradley, Section Editor)

Cardiovascular Complications of Cranial and Neck Radiation

Cardio-oncology (M Fradley, Section Editor)

Use of Noninvasive Imaging in Cardiac Amyloidosis

Cardio-oncology (M Fradley, Section Editor)

Late Cardiotoxicity: Issues for Childhood Cancer Survivors

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.